MIST Milestone Pharmaceuticals Inc.

Nasdaq milestonepharma.com


$ 1.89 $ -0.01 (-0.53 %)    

Friday, 24-Oct-2025 18:04:00 EDT
QQQ $ 617.25 $ 6.52 (1.07 %)
DIA $ 472.51 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.40 $ 0.04 (0.04 %)
GLD $ 378.36 $ -1.27 (-0.34 %)
$ 1.88
$ 1.91
$ 1.87 x 1
$ 1.91 x 1,000
$ 1.86 - $ 1.93
$ 0.63 - $ 2.75
1,453,178
na
159.79M
$ 1.06
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-21-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-29-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-10-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-24-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-11-2021 06-30-2021 10-Q
18 05-17-2021 03-31-2021 10-Q
19 03-29-2021 12-31-2020 10-K
20 11-13-2020 09-30-2020 10-Q
21 08-12-2020 06-30-2020 10-Q
22 05-14-2020 03-31-2020 10-Q
23 03-06-2020 12-31-2019 10-K
24 11-13-2019 09-30-2019 10-Q
25 08-13-2019 06-30-2019 10-Q
26 06-19-2019 03-31-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wells-fargo-initiates-coverage-on-milestone-pharmaceuticals-with-overweight-rating-announces-price-target-of-4

Wells Fargo analyst Mohit Bansal initiates coverage on Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight rating and ...

 milestone-pharmaceuticals-q2-eps-020-misses-017-estimate

Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.20) per share which missed the analyst consensus estim...

 why-is-milestone-pharmaceuticals-stock-plunging-on-friday

FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $52.5 million to support pot...

 milestone-pharma-prices-525m-equity-offering-with-warrants-offering-is-expected-to-close-on-or-about-july-14-2025

Milestone® Pharmaceuticals Inc. ("Milestone") (NASDAQ:MIST), a biopharmaceutical company focused on the development and...

 hc-wainwright--co-assumes-milestone-pharmaceuticals-at-buy-announces-price-target-of-5

HC Wainwright & Co. analyst Brandon Folkes assumes Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy rating and announc...

 milestone-pharmaceuticals-q1-eps-031-misses-018-estimate

Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.31) per share which missed the analyst consensus estim...

 hc-wainwright--co-maintains-buy-on-milestone-pharmaceuticals-lowers-price-target-to-10

HC Wainwright & Co. analyst Patrick Trucchio maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and lowers the...

 hc-wainwright--co-reiterates-buy-on-milestone-pharmaceuticals-maintains-25-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains...

 why-is-milestone-pharmaceuticals-stock-plunging-today

Milestone Pharmaceuticals' stock drops over 61% after receiving a Complete Response Letter from the FDA for its CARDAMYST NDA.

 milestone-pharmaceuticals-says-fda-issued-complete-response-letter-regarding-its-new-drug-application-for-cardamyst-nasal-spray

The FDA did not raise any concerns regarding etripamil clinical safety or efficacy data and highlighted two key Chemistry, Manu...

 hc-wainwright--co-reiterates-buy-on-milestone-pharmaceuticals-maintains-25-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION